Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations

BACKGROUND: Different approaches have been proved effective for combating the COVID-19 pandemic. Accordingly, in silico drug repurposing strategy, has been highly regarded as an accurate computational tool to achieve fast and reliable results. Considering SARS-CoV-2's structural proteins and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahdian, Soodeh, Zarrabi, Mahboobeh, Panahi, Yunes, Dabbagh, Somayyeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904474/
https://www.ncbi.nlm.nih.gov/pubmed/33649734
http://dx.doi.org/10.1016/j.imu.2021.100541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904474/
https://www.ncbi.nlm.nih.gov/pubmed/33649734
http://dx.doi.org/10.1016/j.imu.2021.100541

Ejemplares similares